首页 > 最新文献

Seminars in nephrology最新文献

英文 中文
Introduction: Learning From Each Other: Pediatric and Adult Perspectives to Optimize Kidney Care Across the Life Span. 引言:相互学习:从儿科和成人角度优化整个生命周期的肾脏护理。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-10-31 DOI: 10.1016/j.semnephrol.2023.151443
Arpana Iyengar, Valerie A Luyckx
{"title":"Introduction: Learning From Each Other: Pediatric and Adult Perspectives to Optimize Kidney Care Across the Life Span.","authors":"Arpana Iyengar, Valerie A Luyckx","doi":"10.1016/j.semnephrol.2023.151443","DOIUrl":"10.1016/j.semnephrol.2023.151443","url":null,"abstract":"","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71426637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glomerular Diseases Across Lifespan: Key Differences in Diagnostic and Therapeutic Approaches. 终生肾小球疾病:诊断和治疗方法的关键差异。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-11-08 DOI: 10.1016/j.semnephrol.2023.151435
Martin Windpessl, Balazs Odler, Ingeborg M Bajema, Duvuru Geetha, Marcus Säemann, Jiwon M Lee, Augusto Vaglio, Andreas Kronbichler

Glomerular diseases are common causes of chronic kidney disease in childhood, adolescence, and adulthood. The epidemiology of glomerular diseases differs between different age groups, with minimal change disease being the leading cause of nephrotic syndrome in childhood, while membranous nephropathy and focal segmental glomerulosclerosis are more common in adulthood. IgA vasculitis is also more common in childhood. Moreover, there is a difference in disease severity with more children presenting with a relapsing form of nephrotic syndrome and a more acute presentation of antineutrophil cytoplasmic antibody-associated vasculitis and concomitant glomerulonephritis, as highlighted by the higher percentage of cellular crescents on kidney biopsy specimens in comparison with older patients. There is also a female preponderance in antineutrophil cytoplasmic antibody-associated vasculitis and more children present with tracheobroncholaryngeal disease. This article aims to summarize differences in the presentation of different glomerular diseases that are encountered commonly by pediatric and adult nephrologists and potential differences in the management.

肾小球疾病是儿童、青少年和成年期慢性肾脏疾病的常见原因。肾小球疾病的流行病学在不同年龄组之间有所不同,微小变化疾病是儿童肾病综合征的主要原因,而膜性肾病和局灶节段性肾小球硬化在成年期更常见。IgA血管炎在儿童期也更常见。此外,疾病严重程度存在差异,更多的儿童表现为复发型肾病综合征,更急性地表现为抗中性粒细胞胞质抗体相关血管炎和伴随的肾小球肾炎,与老年患者相比,肾活检标本中细胞新月体的百分比更高。女性在抗中性粒细胞胞浆抗体相关血管炎中也占优势,更多的儿童患有气管支气管喉疾病。本文旨在总结儿童和成人肾脏病学家常见的不同肾小球疾病的表现差异,以及治疗中的潜在差异。
{"title":"Glomerular Diseases Across Lifespan: Key Differences in Diagnostic and Therapeutic Approaches.","authors":"Martin Windpessl, Balazs Odler, Ingeborg M Bajema, Duvuru Geetha, Marcus Säemann, Jiwon M Lee, Augusto Vaglio, Andreas Kronbichler","doi":"10.1016/j.semnephrol.2023.151435","DOIUrl":"10.1016/j.semnephrol.2023.151435","url":null,"abstract":"<p><p>Glomerular diseases are common causes of chronic kidney disease in childhood, adolescence, and adulthood. The epidemiology of glomerular diseases differs between different age groups, with minimal change disease being the leading cause of nephrotic syndrome in childhood, while membranous nephropathy and focal segmental glomerulosclerosis are more common in adulthood. IgA vasculitis is also more common in childhood. Moreover, there is a difference in disease severity with more children presenting with a relapsing form of nephrotic syndrome and a more acute presentation of antineutrophil cytoplasmic antibody-associated vasculitis and concomitant glomerulonephritis, as highlighted by the higher percentage of cellular crescents on kidney biopsy specimens in comparison with older patients. There is also a female preponderance in antineutrophil cytoplasmic antibody-associated vasculitis and more children present with tracheobroncholaryngeal disease. This article aims to summarize differences in the presentation of different glomerular diseases that are encountered commonly by pediatric and adult nephrologists and potential differences in the management.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72015333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management. 儿童和成人囊性肾病:临床管理的差异和差距。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-11-22 DOI: 10.1016/j.semnephrol.2023.151434
Christian Hanna, Ioan-Andrei Iliuta, Whitney Besse, Djalila Mekahli, Fouad T Chebib

Cystic kidney diseases, when broadly defined, have a wide differential diagnosis extending from recessive diseases with a prenatal or pediatric diagnosis, to the most common autosomal-dominant polycystic kidney disease primarily affecting adults, and several other genetic or acquired etiologies that can manifest with kidney cysts. The most likely diagnoses to consider when assessing a patient with cystic kidney disease differ depending on family history, age stratum, radiologic characteristics, and extrarenal features. Accurate identification of the underlying condition is crucial to estimate the prognosis and initiate the appropriate management, identification of extrarenal manifestations, and counseling on recurrence risk in future pregnancies. There are significant differences in the clinical approach to investigating and managing kidney cysts in children compared with adults. Next-generation sequencing has revolutionized the diagnosis of inherited disorders of the kidney, despite limitations in access and challenges in interpreting the data. Disease-modifying treatments are lacking in the majority of kidney cystic diseases. For adults with rapid progressive autosomal-dominant polycystic kidney disease, tolvaptan (V2-receptor antagonist) has been approved to slow the rate of decline in kidney function. In this article, we examine the differences in the differential diagnosis and clinical management of cystic kidney disease in children versus adults, and we highlight the progress in molecular diagnostics and therapeutics, as well as some of the gaps meriting further attention.

囊性肾病,当广义定义时,具有广泛的鉴别诊断,从产前或儿科诊断的隐性疾病,到主要影响成人的最常见的常染色体显性多囊性肾病,以及其他几种可表现为肾囊肿的遗传或获得性病因。在评估囊性肾病患者时,最可能考虑的诊断取决于家族史、年龄层、放射学特征和肾外特征。准确识别潜在的条件是至关重要的估计预后和开始适当的管理,识别外表现,并咨询在未来怀孕复发的风险。与成人相比,儿童肾囊肿的临床调查和治疗方法有显著差异。下一代测序已经彻底改变了遗传性肾脏疾病的诊断,尽管在获取和解释数据方面存在限制和挑战。大多数肾囊性疾病缺乏改善疾病的治疗方法。对于患有快速进行性常染色体显性多囊肾病的成人,托伐普坦(v2受体拮抗剂)已被批准用于减缓肾功能下降的速度。在这篇文章中,我们检查了儿童与成人囊性肾病的鉴别诊断和临床管理的差异,我们强调了分子诊断和治疗的进展,以及一些值得进一步关注的差距。
{"title":"Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management.","authors":"Christian Hanna, Ioan-Andrei Iliuta, Whitney Besse, Djalila Mekahli, Fouad T Chebib","doi":"10.1016/j.semnephrol.2023.151434","DOIUrl":"10.1016/j.semnephrol.2023.151434","url":null,"abstract":"<p><p>Cystic kidney diseases, when broadly defined, have a wide differential diagnosis extending from recessive diseases with a prenatal or pediatric diagnosis, to the most common autosomal-dominant polycystic kidney disease primarily affecting adults, and several other genetic or acquired etiologies that can manifest with kidney cysts. The most likely diagnoses to consider when assessing a patient with cystic kidney disease differ depending on family history, age stratum, radiologic characteristics, and extrarenal features. Accurate identification of the underlying condition is crucial to estimate the prognosis and initiate the appropriate management, identification of extrarenal manifestations, and counseling on recurrence risk in future pregnancies. There are significant differences in the clinical approach to investigating and managing kidney cysts in children compared with adults. Next-generation sequencing has revolutionized the diagnosis of inherited disorders of the kidney, despite limitations in access and challenges in interpreting the data. Disease-modifying treatments are lacking in the majority of kidney cystic diseases. For adults with rapid progressive autosomal-dominant polycystic kidney disease, tolvaptan (V2-receptor antagonist) has been approved to slow the rate of decline in kidney function. In this article, we examine the differences in the differential diagnosis and clinical management of cystic kidney disease in children versus adults, and we highlight the progress in molecular diagnostics and therapeutics, as well as some of the gaps meriting further attention.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138299946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tubular Diseases and Stones Seen From Pediatric and Adult Nephrology Perspectives. 从儿童和成人肾脏学的角度看肾小管疾病和结石。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-11-14 DOI: 10.1016/j.semnephrol.2023.151437
Johannes Münch, Paul R Goodyer, Carsten A Wagner

The tubular system of the kidneys is a complex series of morphologic and functional units orchestrating the content of tubular fluid as it flows along the nephron and collecting ducts. Renal tubules maintain body water, regulate electrolytes and acid-base balance, reabsorb precious organic solutes, and eliminate specific metabolites, toxins, and drugs. In addition, decisive mechanisms to adjust blood pressure are governed by the renal tubules. Genetic as well as acquired disorders of these tubular functions may cause serious diseases that manifest both in childhood and adulthood. This article addresses a selection of tubulopathies and the underlying pathomechanisms, while highlighting the important differences in pediatric and adult nephrology care. These range from rare monogenic conditions such as nephrogenic diabetes insipidus, cystinosis, and Bartter syndrome that present in childhood, to the genetic and acquired tubular pathologies causing hypertension or nephrolithiasis that are more prevalent in adults. Both pediatric and adult nephrologists must be aware of these conditions and the age-dependent manifestations that warrant close interaction between the two subspecialties.

肾脏的管状系统是由一系列复杂的形态和功能单位组成的,当管状液体沿着肾元和收集管流动时,它会协调管状液体的内容。肾小管维持体内水分,调节电解质和酸碱平衡,重新吸收宝贵的有机溶质,并消除特定的代谢物、毒素和药物。此外,调节血压的决定性机制是由肾小管控制的。这些小管功能的遗传和获得性障碍可能导致儿童和成年期出现的严重疾病。这篇文章讨论了小管病变的选择和潜在的病理机制,同时强调了儿科和成人肾病护理的重要差异。这些疾病包括罕见的单基因疾病,如儿童时期出现的肾源性尿崩症、胱氨酸病和巴特综合征,以及在成人中更为普遍的遗传和获得性肾小管病变,导致高血压或肾结石。儿科和成人肾病学家都必须意识到这些情况和年龄依赖性的表现,保证两个亚专科之间的密切互动。
{"title":"Tubular Diseases and Stones Seen From Pediatric and Adult Nephrology Perspectives.","authors":"Johannes Münch, Paul R Goodyer, Carsten A Wagner","doi":"10.1016/j.semnephrol.2023.151437","DOIUrl":"10.1016/j.semnephrol.2023.151437","url":null,"abstract":"<p><p>The tubular system of the kidneys is a complex series of morphologic and functional units orchestrating the content of tubular fluid as it flows along the nephron and collecting ducts. Renal tubules maintain body water, regulate electrolytes and acid-base balance, reabsorb precious organic solutes, and eliminate specific metabolites, toxins, and drugs. In addition, decisive mechanisms to adjust blood pressure are governed by the renal tubules. Genetic as well as acquired disorders of these tubular functions may cause serious diseases that manifest both in childhood and adulthood. This article addresses a selection of tubulopathies and the underlying pathomechanisms, while highlighting the important differences in pediatric and adult nephrology care. These range from rare monogenic conditions such as nephrogenic diabetes insipidus, cystinosis, and Bartter syndrome that present in childhood, to the genetic and acquired tubular pathologies causing hypertension or nephrolithiasis that are more prevalent in adults. Both pediatric and adult nephrologists must be aware of these conditions and the age-dependent manifestations that warrant close interaction between the two subspecialties.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury: Gaps and Opportunities for Knowledge and Growth. 急性肾损伤:知识和成长的差距和机会。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-11-13 DOI: 10.1016/j.semnephrol.2023.151439
Rolando Claure-Del Granado, Javier A Neyra, Rajit K Basu

Acute kidney injury (AKI) occurs frequently in hospitalized patients, regardless of age or prior medical history. Increasing awareness of the epidemiologic problem of AKI has directly led to increased study of global recognition, diagnostic tools, both reactive and proactive management, and analysis of long-term sequelae. Many gaps remain, however, and in this article we highlight opportunities to add significantly to the increasing bodies of evidence surrounding AKI. Practical considerations related to initiation, prescription, anticoagulation, and monitoring are discussed. In addition, the importance of AKI follow-up evaluation, particularly for those surviving the receipt of renal replacement therapy, is highlighted as a push for global equity in the realm of critical care nephrology is broached. Addressing these gaps presents an opportunity to impact patient care directly and improve patient outcomes.

急性肾损伤(AKI)常见于住院患者,与年龄或既往病史无关。对AKI流行病学问题的认识不断提高,直接导致了对全球认知、诊断工具、被动和主动管理以及长期后遗症分析的研究增加。然而,许多差距仍然存在,在本文中,我们强调了增加AKI相关证据的机会。讨论了有关起始、处方、抗凝和监测的实际考虑。此外,AKI随访评估的重要性,特别是对于那些接受肾脏替代治疗的幸存者,随着在重症肾病学领域推动全球公平的提出而得到强调。解决这些差距为直接影响患者护理和改善患者预后提供了机会。
{"title":"Acute Kidney Injury: Gaps and Opportunities for Knowledge and Growth.","authors":"Rolando Claure-Del Granado, Javier A Neyra, Rajit K Basu","doi":"10.1016/j.semnephrol.2023.151439","DOIUrl":"10.1016/j.semnephrol.2023.151439","url":null,"abstract":"<p><p>Acute kidney injury (AKI) occurs frequently in hospitalized patients, regardless of age or prior medical history. Increasing awareness of the epidemiologic problem of AKI has directly led to increased study of global recognition, diagnostic tools, both reactive and proactive management, and analysis of long-term sequelae. Many gaps remain, however, and in this article we highlight opportunities to add significantly to the increasing bodies of evidence surrounding AKI. Practical considerations related to initiation, prescription, anticoagulation, and monitoring are discussed. In addition, the importance of AKI follow-up evaluation, particularly for those surviving the receipt of renal replacement therapy, is highlighted as a push for global equity in the realm of critical care nephrology is broached. Addressing these gaps presents an opportunity to impact patient care directly and improve patient outcomes.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutrition Management for Chronic Kidney Disease: Differences and Special Needs for Children and Adults. 慢性肾脏疾病的营养管理:儿童和成人的差异和特殊需要。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-07-01 Epub Date: 2023-11-18 DOI: 10.1016/j.semnephrol.2023.151441
Robert H Mak, Arpana Iyengar, Angela Yee-Moon Wang

Common goals of nutritional therapy across the spectrum of pediatric and adult chronic kidney disease (CKD) include maintaining normal body mass and composition and reducing associated morbidity and mortality. Adult nephrologists caring for children and adolescents may be challenged by the existing complexities in identifying and interpreting the nutritional status and growth in children. Pediatric nephrologists may face situations that call for a sound knowledge of assessing nutritional status and providing nutrition therapy for adolescents and young adults. One important additional nutrition goal in children is to achieve normal growth and development. Children are growing and therefore need more calories and nutrients than just maintaining their body weight and composition. Lack of weight and height gain actually is considered failure to thrive in children. Some fundamental differences in approaches to nutritional therapy in CKD are necessitated based on the etiology of CKD. A large proportion of adults with CKD are diabetics, so the approach would be a low-carbohydrate diet. Children with CKD, especially young ones, often are anorexic, so calorie supplements that could include quite a lot of carbohydrates often are prescribed. More adults with CKD have hypertension and atherosclerotic comorbidities, which result in recommendations for low-salt and low-fat diets. Children with CKD often have salt and electrolyte wasting disease states and would require normal- or even high-salt diets, and fats often are included in supplements to bolster calorie intake. Low-protein diets often are recommended in adults with predialysis CKD to slow disease progression. Children are growing and have a higher protein daily requirement. Low-protein diets have not been found to be efficacious in children with CKD, in achieving normal growth, or in slowing disease progression. Adult nephrologists caring for children and adolescents may be challenged by the existing complexities in identifying and interpreting nutritional status and growth in children. Pediatric nephrologists may face situations that call for a sound knowledge of assessing nutritional status and providing nutrition therapy for adolescents and young adults. This article discusses the differences in the assessment of nutritional status between children and adults, as well as provides a comprehensive approach to nutritional management for CKD across the age spectrum. Semin Nephrol 43:x-xx © 2023 Elsevier Inc. All rights reserved.

儿童和成人慢性肾脏疾病(CKD)营养治疗的共同目标包括维持正常的体重和组成,降低相关的发病率和死亡率。照顾儿童和青少年的成人肾病学家可能会受到识别和解释儿童营养状况和生长发育的复杂性的挑战。儿科肾病学家可能面临的情况,需要一个健全的知识评估营养状况和提供营养治疗的青少年和年轻人。儿童的另一个重要营养目标是实现正常的生长发育。孩子们正在成长,因此需要更多的卡路里和营养,而不仅仅是维持他们的体重和身体成分。体重和身高增加不足实际上被认为是儿童成长的失败。根据CKD的病因,需要在CKD的营养治疗方法上有一些根本的区别。成人慢性肾病患者中有很大一部分是糖尿病患者,因此治疗方法是低碳水化合物饮食。患有慢性肾病的儿童,尤其是年幼的儿童,通常患有厌食症,因此医生通常会开出含有大量碳水化合物的卡路里补充剂。越来越多的成人慢性肾病患者有高血压和动脉粥样硬化合并症,因此建议采用低盐和低脂饮食。患有慢性肾病的儿童通常有盐和电解质消耗疾病状态,需要正常甚至高盐饮食,并且脂肪通常包含在补充剂中以增加卡路里摄入量。透析前CKD患者通常推荐低蛋白饮食以减缓疾病进展。孩子们正在成长,每天对蛋白质的需求量更高。目前还没有发现低蛋白饮食对CKD患儿、实现正常生长或减缓疾病进展有效。照顾儿童和青少年的成人肾病学家可能会受到识别和解释儿童营养状况和生长的复杂性的挑战。儿科肾病学家可能面临的情况,需要一个健全的知识评估营养状况和提供营养治疗的青少年和年轻人。本文讨论了儿童和成人之间营养状况评估的差异,并提供了跨年龄范围CKD营养管理的综合方法。Semin Nephrol 43:x-xx©2023 Elsevier Inc.。版权所有。
{"title":"Nutrition Management for Chronic Kidney Disease: Differences and Special Needs for Children and Adults.","authors":"Robert H Mak, Arpana Iyengar, Angela Yee-Moon Wang","doi":"10.1016/j.semnephrol.2023.151441","DOIUrl":"10.1016/j.semnephrol.2023.151441","url":null,"abstract":"<p><p>Common goals of nutritional therapy across the spectrum of pediatric and adult chronic kidney disease (CKD) include maintaining normal body mass and composition and reducing associated morbidity and mortality. Adult nephrologists caring for children and adolescents may be challenged by the existing complexities in identifying and interpreting the nutritional status and growth in children. Pediatric nephrologists may face situations that call for a sound knowledge of assessing nutritional status and providing nutrition therapy for adolescents and young adults. One important additional nutrition goal in children is to achieve normal growth and development. Children are growing and therefore need more calories and nutrients than just maintaining their body weight and composition. Lack of weight and height gain actually is considered failure to thrive in children. Some fundamental differences in approaches to nutritional therapy in CKD are necessitated based on the etiology of CKD. A large proportion of adults with CKD are diabetics, so the approach would be a low-carbohydrate diet. Children with CKD, especially young ones, often are anorexic, so calorie supplements that could include quite a lot of carbohydrates often are prescribed. More adults with CKD have hypertension and atherosclerotic comorbidities, which result in recommendations for low-salt and low-fat diets. Children with CKD often have salt and electrolyte wasting disease states and would require normal- or even high-salt diets, and fats often are included in supplements to bolster calorie intake. Low-protein diets often are recommended in adults with predialysis CKD to slow disease progression. Children are growing and have a higher protein daily requirement. Low-protein diets have not been found to be efficacious in children with CKD, in achieving normal growth, or in slowing disease progression. Adult nephrologists caring for children and adolescents may be challenged by the existing complexities in identifying and interpreting nutritional status and growth in children. Pediatric nephrologists may face situations that call for a sound knowledge of assessing nutritional status and providing nutrition therapy for adolescents and young adults. This article discusses the differences in the assessment of nutritional status between children and adults, as well as provides a comprehensive approach to nutritional management for CKD across the age spectrum. Semin Nephrol 43:x-xx © 2023 Elsevier Inc. All rights reserved.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Inflammation in Progression of Chronic Kidney Disease in Type 2 Diabetes Mellitus: Clinical Implications 炎症在2型糖尿病慢性肾脏疾病进展中的作用:临床意义。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-05-01 DOI: 10.1016/j.semnephrol.2023.151431
Yasuhiro Oda MD, Hiroshi Nishi MD, PhD, Masaomi Nangaku MD, PhD

Progression of chronic kidney disease in type 2 diabetes has been understood conventionally as a consequence of intraglomerular hemodynamic changes and aberrant metabolic pathways. However, an increasing body of experimental evidence has highlighted the role of inflammatory response in the progression of diabetic kidney disease. Macrophage polarization in response to specific microenvironmental stimuli affects the pathology of diabetic kidneys. The diabetic milieu also up-regulates inflammatory cytokines, chemokines, and adhesion molecules, and promotes inflammatory signal transduction pathways, including inflammasomes. Therefore, from a reverse translational perspective, modulation of the inflammatory response may be the driving force of the renoprotective effects of renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, and mineralocorticoid receptor antagonists, all of which have been shown to slow disease progression. Currently, many agents that target the inflammation in the kidneys directly are evaluated in clinical trials. This article discusses recent clinical and experimental milestones in drug development for diabetic kidney disease with a perspective on inflammation in the kidneys. Such insights may enable a targeted approach to discovering novel drugs against chronic kidney disease in type 2 diabetes.

2型糖尿病中慢性肾脏疾病的进展通常被理解为肾小球内血液动力学变化和异常代谢途径的结果。然而,越来越多的实验证据强调了炎症反应在糖尿病肾病进展中的作用。巨噬细胞对特定微环境刺激的极化影响糖尿病肾脏的病理学。糖尿病环境还上调炎症细胞因子、趋化因子和粘附分子,并促进炎症信号转导途径,包括炎症小体。因此,从反翻译的角度来看,炎症反应的调节可能是肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂和盐皮质激素受体拮抗剂的肾脏保护作用的驱动力,所有这些都已被证明可以减缓疾病进展。目前,许多直接针对肾脏炎症的药物在临床试验中进行了评估。本文从肾脏炎症的角度讨论了糖尿病肾病药物开发的最新临床和实验里程碑。这些见解可能使我们能够有针对性地发现治疗2型糖尿病慢性肾脏疾病的新药。
{"title":"Role of Inflammation in Progression of Chronic Kidney Disease in Type 2 Diabetes Mellitus: Clinical Implications","authors":"Yasuhiro Oda MD,&nbsp;Hiroshi Nishi MD, PhD,&nbsp;Masaomi Nangaku MD, PhD","doi":"10.1016/j.semnephrol.2023.151431","DOIUrl":"10.1016/j.semnephrol.2023.151431","url":null,"abstract":"<div><p><span><span>Progression of chronic kidney disease<span> in type 2 diabetes has been understood conventionally as a consequence of intraglomerular hemodynamic changes and aberrant metabolic pathways. However, an increasing body of experimental evidence has highlighted the role of inflammatory response in the progression of </span></span>diabetic kidney disease<span><span><span><span>. Macrophage polarization in response to specific microenvironmental stimuli affects the pathology of diabetic kidneys. The diabetic milieu also up-regulates </span>inflammatory cytokines, </span>chemokines, and </span>adhesion molecules<span>, and promotes inflammatory signal transduction pathways<span><span>, including inflammasomes. Therefore, from a reverse translational perspective, modulation of the inflammatory response may be the driving force of the renoprotective effects of renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, and </span>mineralocorticoid receptor antagonists<span>, all of which have been shown to slow disease progression. Currently, many agents that target the inflammation in the kidneys directly are evaluated in </span></span></span></span></span>clinical trials<span>. This article discusses recent clinical and experimental milestones in drug development for diabetic kidney disease with a perspective on inflammation in the kidneys. Such insights may enable a targeted approach to discovering novel drugs against chronic kidney disease in type 2 diabetes.</span></p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flattening the Playing Field for Treatment of Diabetic Kidney Disease 为糖尿病肾病的治疗铺平道路。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-05-01 DOI: 10.1016/j.semnephrol.2023.151428
Keith C. Norris MD, PhD , Sandra F. Williams DMD, MB , Robert Nee MD

Diabetic kidney disease (DKD) remains a major health care issue and is beset with significant racial and ethnic disparities in regard to its incidence, progression, and complication rate. An individual's health is influenced strongly by an array of societal-level factors commonly called the social determinants of health. Among these, DKD is influenced highly by structured resources and opportunities, as well as an individual's socioeconomic status, health insurance status, access to care, education, health literacy, nutrition, green space exposure, level of trust in the medical community, and more. Health equity is considered a state in which everyone has a fair and just opportunity to attain his or her highest level of health. Conversely, health inequities are a consequence of a structured discriminatory system of inequitable allocation of social determinants of health. When this discriminatory system is race-based it is referred to as structural racism, which eventually leads to racial and ethnic health disparities. The further downstream sequela of structural racism, consciously or unconsciously, impacts health systems, providers, and patients, and can lead to disparities in DKD development, progression, and complications. In this article, we explore potential interventions at the societal, health system, and provider levels that can help flatten the playing field and reduce racial and ethnic disparities in DKD.

糖尿病肾病(DKD)仍然是一个主要的医疗保健问题,在发病率、进展和并发症发生率方面存在显著的种族和民族差异。一个人的健康受到一系列社会层面因素的强烈影响,这些因素通常被称为健康的社会决定因素。其中,DKD在很大程度上受到结构性资源和机会的影响,以及个人的社会经济地位、医疗保险状况、获得护理的机会、教育、健康知识、营养、绿地暴露、对医疗界的信任程度等。健康公平被认为是一种状态,在这种状态下,每个人都有公平公正的机会达到自己的最高健康水平。相反,健康不平等是健康的社会决定因素分配不公平的结构性歧视性制度的结果。当这种歧视性制度基于种族时,它被称为结构性种族主义,最终导致种族和族裔健康差异。结构性种族主义的进一步下游后遗症,有意识或无意识地影响着卫生系统、提供者和患者,并可能导致DKD发展、进展和并发症的差异。在这篇文章中,我们探讨了社会、卫生系统和提供者层面的潜在干预措施,这些干预措施有助于平整DKD的竞争环境,减少DKD的种族和民族差异。
{"title":"Flattening the Playing Field for Treatment of Diabetic Kidney Disease","authors":"Keith C. Norris MD, PhD ,&nbsp;Sandra F. Williams DMD, MB ,&nbsp;Robert Nee MD","doi":"10.1016/j.semnephrol.2023.151428","DOIUrl":"10.1016/j.semnephrol.2023.151428","url":null,"abstract":"<div><p>Diabetic kidney disease (DKD) remains a major health care issue and is beset with significant racial and ethnic disparities in regard to its incidence, progression, and complication rate. An individual's health is influenced strongly by an array of societal-level factors commonly called the <em>social determinants of health</em>. Among these, DKD is influenced highly by structured resources and opportunities, as well as an individual's socioeconomic status, health insurance status, access to care, education, health literacy, nutrition, green space exposure, level of trust in the medical community, and more. Health equity is considered a state in which everyone has a fair and just opportunity to attain his or her highest level of health. Conversely, health inequities are a consequence of a structured discriminatory system of inequitable allocation of social determinants of health. When this discriminatory system is race-based it is referred to as <em>structural racism</em>, which eventually leads to racial and ethnic health disparities. The further downstream sequela of structural racism, consciously or unconsciously, impacts health systems, providers, and patients, and can lead to disparities in DKD development, progression, and complications. In this article, we explore potential interventions at the societal, health system, and provider levels that can help flatten the playing field and reduce racial and ethnic disparities in DKD.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0270929523001389/pdfft?md5=8da2a2adae7b67bb92525d4b6dcbd70a&pid=1-s2.0-S0270929523001389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sixty Years of Confronting Diabetes and Kidney Disease 对抗糖尿病和肾脏疾病60年。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-05-01 DOI: 10.1016/j.semnephrol.2023.151426
Friedrich C. Luft MD

The good old days were not good, at least in terms of treating patients with type 2 diabetes. In the 1960s, the development of a radioimmunoassay for insulin permitted determination of the distinguishing features of type 1 and type 2 diabetes. The latter was treated with sulfonylureas and then phenformin, although the mechanisms of action at the time were unknown. The University Group Diabetes Program was a randomized controlled trial experienced by my medical generation, and the results were dramatic, both medically and legally. Next came the thiazolidinediones. All compounds were associated with weight gain and any end point benefits were uncertain. Nevertheless, basic science explained how glucose is sensed and even found a home for sulfonylureas in some patients. Next came the boom in renin-angiotensin-aldosterone system blockade, sacred ground for many, albeit the benefits were less than astounding. Other wonder drugs came and went. Over the decades, great strides were made in defining the pathology of diabetic renal disease, which is appropriate because the condition has become a primary cause of end-stage renal failure. Nonetheless, recent advances have turned around a depressing situation and are reasons for optimism. We now have compounds that actually could help patients with type 2 diabetes. One hundred years after insulin's introduction, it is high time.

过去的好日子并不好,至少在治疗2型糖尿病患者方面是这样。在20世纪60年代,胰岛素放射免疫分析法的发展允许确定1型和2型糖尿病的区别特征。后者先用磺脲类药物治疗,然后用苯乙双胍治疗,尽管当时的作用机制尚不清楚。大学糖尿病小组项目是我这一代医学界经历的一项随机对照试验,无论在医学上还是在法律上,结果都是惊人的。接下来是噻唑烷二酮。所有化合物都与体重增加有关,任何终点益处都不确定。尽管如此,基础科学解释了葡萄糖是如何被感知的,甚至为一些患者找到了磺酰脲类药物的归宿。接下来是肾素-血管紧张素-醛固酮系统阻断的繁荣,这是许多人的圣地,尽管其益处并不惊人。其他神奇的药物来来往往。几十年来,在定义糖尿病肾病的病理学方面取得了巨大进展,这是合适的,因为糖尿病肾病已成为终末期肾功能衰竭的主要原因。尽管如此,最近的进展扭转了令人沮丧的局面,是乐观的理由。我们现在有了可以帮助2型糖尿病患者的化合物。胰岛素问世一百年后,是时候了。
{"title":"Sixty Years of Confronting Diabetes and Kidney Disease","authors":"Friedrich C. Luft MD","doi":"10.1016/j.semnephrol.2023.151426","DOIUrl":"10.1016/j.semnephrol.2023.151426","url":null,"abstract":"<div><p>The good old days were not good, at least in terms of treating patients with type 2 diabetes. In the 1960s, the development of a radioimmunoassay for insulin permitted determination of the distinguishing features of type 1 and type 2 diabetes. The latter was treated with sulfonylureas and then phenformin, although the mechanisms of action at the time were unknown. The University Group Diabetes Program was a randomized controlled trial experienced by my medical generation, and the results were dramatic, both medically and legally. Next came the thiazolidinediones. All compounds were associated with weight gain and any end point benefits were uncertain. Nevertheless, basic science explained how glucose is sensed and even found a home for sulfonylureas in some patients. Next came the boom in renin-angiotensin-aldosterone system blockade, sacred ground for many, albeit the benefits were less than astounding. Other wonder drugs came and went. Over the decades, great strides were made in defining the pathology of diabetic renal disease, which is appropriate because the condition has become a primary cause of end-stage renal failure. Nonetheless, recent advances have turned around a depressing situation and are reasons for optimism. We now have compounds that actually could help patients with type 2 diabetes. One hundred years after insulin's introduction, it is high time.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease 纳入糖尿病和慢性肾脏疾病个性化护理的证据和指南。
IF 3.3 3区 医学 Q1 Medicine Pub Date : 2023-05-01 DOI: 10.1016/j.semnephrol.2023.151427
Joshua J. Neumiller PharmD , Radica Z. Alicic MD , Katherine R. Tuttle MD

Chronic kidney disease (CKD) represents a particularly challenging diabetes complication. Diabetes now is responsible for half of all cases of CKD, thus making diabetes the most common cause of kidney failure worldwide. In patients with diabetes, CKD frequently coexists with heart failure and atherosclerotic cardiovascular disease, which together are associated with marked increases in the risk of cardiovascular and all-cause mortality. Fortunately, new therapeutic agents from several classes now are available with proven benefits for kidney and heart protection when used in patients with type 2 diabetes and CKD. Agents from the sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1–receptor agonist, and nonsteroidal mineralocorticoid-receptor antagonist classes now are considered standard of care to improve kidney, heart, and overall survival outcomes in patients with type 2 diabetes. Efforts to educate health care providers on the benefits of these therapies are critically needed to help increase their utilization and improve clinical outcomes. Care decisions should be driven by a holistic view of patient priorities and goals with consideration of a multimodal therapeutic approach to maximize heart and kidney benefits.

慢性肾脏疾病(CKD)是一种特别具有挑战性的糖尿病并发症。糖尿病现在占CKD病例的一半,因此使糖尿病成为全球肾衰竭最常见的原因。在糖尿病患者中,CKD经常与心力衰竭和动脉粥样硬化性心血管疾病共存,这两种疾病共同导致心血管和全因死亡率的显著增加。幸运的是,现在有几种新的治疗剂可用于2型糖尿病和CKD患者,它们已被证明对肾脏和心脏有保护作用。钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂和非甾体盐皮质激素受体拮抗剂类药物现在被认为是改善2型糖尿病患者肾脏、心脏和总体生存结果的标准护理。迫切需要努力教育医疗保健提供者了解这些疗法的好处,以帮助提高其利用率并改善临床结果。护理决策应以患者优先事项和目标的整体观点为驱动,同时考虑多模式治疗方法,以最大限度地提高心脏和肾脏的益处。
{"title":"Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease","authors":"Joshua J. Neumiller PharmD ,&nbsp;Radica Z. Alicic MD ,&nbsp;Katherine R. Tuttle MD","doi":"10.1016/j.semnephrol.2023.151427","DOIUrl":"10.1016/j.semnephrol.2023.151427","url":null,"abstract":"<div><p>Chronic kidney disease (CKD) represents a particularly challenging diabetes complication. Diabetes now is responsible for half of all cases of CKD, thus making diabetes the most common cause of kidney failure worldwide. In patients with diabetes, CKD frequently coexists with heart failure and atherosclerotic cardiovascular disease, which together are associated with marked increases in the risk of cardiovascular and all-cause mortality. Fortunately, new therapeutic agents from several classes now are available with proven benefits for kidney and heart protection when used in patients with type 2 diabetes and CKD. Agents from the sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1–receptor agonist, and nonsteroidal mineralocorticoid-receptor antagonist classes now are considered standard of care to improve kidney, heart, and overall survival outcomes in patients with type 2 diabetes. Efforts to educate health care providers on the benefits of these therapies are critically needed to help increase their utilization and improve clinical outcomes. Care decisions should be driven by a holistic view of patient priorities and goals with consideration of a multimodal therapeutic approach to maximize heart and kidney benefits.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1